The FDA's review of the Moderna vaccine for teens could take until January 2022
The Food and Drug Administration needs more time to complete its assessment of Moderna's COVID-19 vaccine for use for 12- to 17-year-olds, the drugmaker said Sunday. The review could take until January 2022 to complete.
Moderna said in May that its vaccine was 100 percent effective in a study of 12- to 17-year-olds. The FDA is now specifically reviewing the risk of myocarditis, an inflammation of the heart muscle. Moderna will wait to file a request for emergency authorization for a smaller dose of its vaccine for children ages 6 to 11 until the FDA completes the review for the teenage group.
The FDA expanded Pfizer's COVID-19 emergency use to include adolescents ages 12 through 15 back in May. On Friday, the FDA further approved Pfizer's COVID-19 vaccine for emergency use authorization for children ages 5 to 11.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Jeva Lange was the executive editor at TheWeek.com. She formerly served as The Week's deputy editor and culture critic. She is also a contributor to Screen Slate, and her writing has appeared in The New York Daily News, The Awl, Vice, and Gothamist, among other publications. Jeva lives in New York City. Follow her on Twitter.
-
Why is Tesla stumbling?
In the Spotlight More competition, confusion about the future and a giant pay package for Elon Musk
By Joel Mathis, The Week US Published
-
How Taylor Swift changed copyright negotiations in music
under the radar The success of Taylor's Version rerecordings has put new pressure on record labels
By Theara Coleman, The Week US Published
-
Job scams are increasingly common. Here's what to look out for.
The Explainer You should never pay for an application or give out your personal info before being hired
By Becca Stanek, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published